Key features and details
- Rabbit polyclonal to Von Willebrand Factor
- Suitable for: IHC-P
- Reacts with: Rat
- Isotype: IgG
Product nameAnti-Von Willebrand Factor antibody
See all Von Willebrand Factor primary antibodies
DescriptionRabbit polyclonal to Von Willebrand Factor
Tested applicationsSuitable for: IHC-Pmore details
Species reactivityReacts with: Rat
Predicted to work with: Human
Synthetic peptide aa 730-780 conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary.
Database link: P04275
- IHC-P: Rat brain tissue.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 50% Glycerol, 1% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab216566 in the following tested applications.
|IHC-P||1/100 - 1/500.|
FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
- Information by UniProt
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
ab216566 has been referenced in 1 publication.
- Geng W et al. Exosomes from miRNA-126-modified ADSCs promotes functional recovery after stroke in rats by improving neurogenesis and suppressing microglia activation. Am J Transl Res 11:780-792 (2019). PubMed: 30899379